Biogen (NASDAQ:BIIB) stockholders approved all three proposals presented at the company’s 2026 annual meeting, including the election of 10 directors, the ratification of PricewaterhouseCoopers as independent auditor and an advisory vote supporting executive compensation.
The virtual meeting was led by Caroline Dorsa, Biogen’s chair of the board, who said a quorum was present and that stockholders of record as of April 21, 2026, were eligible to vote. Wendell Taylor, Biogen’s chief corporation counsel, served as secretary of the meeting. Dorsa said Jennifer Borden of Borden Consulting Group LLC was appointed as the independent inspector of elections.
Directors Elected for One-Year Terms
The board had recommended that stockholders vote in favor of each nominee. Viehbacher, Biogen’s president and chief executive officer, is also a member of the board.
PwC Ratified as Auditor
Stockholders also ratified the audit committee’s selection of PricewaterhouseCoopers as Biogen’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. Mark Barsanti, a representative of PwC, participated in the meeting and was available to answer questions.
In addition, Dorsa said a majority of stockholders voted in favor of the advisory proposal on executive compensation. No stockholder questions were submitted regarding the proposals, according to Taylor.
Dorsa said the final voting results will be filed with the Securities and Exchange Commission on Form 8-K within four business days.
Dorsa Concludes Board Service
After the formal business concluded, Dorsa noted that her service as a director and chair of the board would end at the close of the meeting. She thanked stockholders for their confidence over the past 16 years and thanked current and former directors for their service.
“Our goal is to continue to pursue our path toward long-term sustainable growth,” Dorsa said. “We believe that Chris and the executive team are well-positioned to drive that progress as we aim to strengthen and diversify our portfolio.”
Dorsa also said she had “strong conviction” that the board, under the leadership of Dr. Maria Freire as incoming chair, together with the management team led by Viehbacher, is well-positioned to guide Biogen through its next chapter of growth.
Executive Team in Attendance
Dorsa said members of Biogen’s executive team attended the meeting, including Ginger Gregory, chief human resources officer; Jane Grogan, head of research; Rachid Izzar, head of global product strategy and commercialization; Adam Keeney, head of corporate development; Robin Kramer, chief financial officer; Nicole Murphy, head of pharmaceutical operations and technology; and Priya Singhal, head of development.
The annual meeting was adjourned after the preliminary voting results were announced.
About Biogen (NASDAQ:BIIB)
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
